Cargando…

Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease

Nonalcoholic fatty liver disease (NAFLD), also named metabolic dysfunction-associated fatty liver disease (MAFLD), is a progressive disease spectrum encompassing simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. It is a clinically silent disease leading to multiple extr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassen, Gashaw, Singh, Abhishek, Belete, Gizeshwork, Jain, Nidhi, De la Hoz, Ivonne, Camacho-Leon, Genesis P, Dargie, Nitsuh K, Carrera, Keila G, Alemu, Tadesse, Jhaveri, Sharan, Solomon, Nebiyou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242599/
https://www.ncbi.nlm.nih.gov/pubmed/35783879
http://dx.doi.org/10.7759/cureus.25495
_version_ 1784738088402026496
author Hassen, Gashaw
Singh, Abhishek
Belete, Gizeshwork
Jain, Nidhi
De la Hoz, Ivonne
Camacho-Leon, Genesis P
Dargie, Nitsuh K
Carrera, Keila G
Alemu, Tadesse
Jhaveri, Sharan
Solomon, Nebiyou
author_facet Hassen, Gashaw
Singh, Abhishek
Belete, Gizeshwork
Jain, Nidhi
De la Hoz, Ivonne
Camacho-Leon, Genesis P
Dargie, Nitsuh K
Carrera, Keila G
Alemu, Tadesse
Jhaveri, Sharan
Solomon, Nebiyou
author_sort Hassen, Gashaw
collection PubMed
description Nonalcoholic fatty liver disease (NAFLD), also named metabolic dysfunction-associated fatty liver disease (MAFLD), is a progressive disease spectrum encompassing simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. It is a clinically silent disease leading to multiple extra-hepatic complications/comorbidities. It is an independent risk factor for cardiovascular disease (CVD), increasing susceptibility to hypertension, atherosclerosis, arrhythmia, myocardial dysfunction, cardiac valve deformation, and venous thrombosis through putative mechanisms including systemic inflammation, endothelial dysfunction, oxidative stress, insulin resistance, and altered lipid metabolism. Eventually, it increases the CVD prevalence, incident, and fatality, contributing to a huge health care burden. In fact, CVD is becoming the leading cause of mortality among patients with NAFLD. Other cardiometabolic risk factors coexisting with NAFLD may also accelerate the synergistic development of CVD, which warrants assessment targeting hypertension, diabetes mellitus (DM), obesity, and dyslipidemia to be an integral part of NAFLD care. Monitoring metabolic biomarkers (glucose, glycosylated hemoglobin [HbA1c], insulin, lipids, and lipoproteins), cardiovascular (CV) risk scores (American College of Cardiology/American Heart Association [ACC/AHA] or Framingham), and subclinical atherosclerosis (coronary artery calcification [CAC], carotid intima-media thickness [CIMT], and carotid plaque) are recommended for risk prediction and reduction. There is no universally accepted treatment for NAFLD, and lifestyle changes with weight loss of at least 10% are the mainstay of management. Combination therapy of ezetimibe and statins have a cardioprotective effect and help reduce liver fat. Despite being an emerging risk factor for CVD and its rapidly increasing pattern affecting a quarter of the global population, NAFLD remains overlooked and undetected, unlike the other traditional risk factors. Hence, we conducted a comprehensive narrative review to shed more light on the importance of screening CVD in NAFLD patients. PubMed indexed relevant articles published from 2002 to 2022 (20 years) were searched in April 2022 using medical subject headings (MeSH) as "nonalcoholic fatty liver disease" [Mesh] AND "cardiovascular diseases" [Mesh]. Evidence from 40 observational studies, three clinical trials, one case series, 45 narrative reviews, four systematic reviews and meta-analyses, three systematic reviews, and one meta-analysis were summarized on the epidemiologic data, pathophysiologic mechanisms, clinical features, diagnostic modalities, overlapping management, perceived challenges and health literacy regarding the CVD risk attributed to NAFLD.
format Online
Article
Text
id pubmed-9242599
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-92425992022-07-02 Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease Hassen, Gashaw Singh, Abhishek Belete, Gizeshwork Jain, Nidhi De la Hoz, Ivonne Camacho-Leon, Genesis P Dargie, Nitsuh K Carrera, Keila G Alemu, Tadesse Jhaveri, Sharan Solomon, Nebiyou Cureus Cardiology Nonalcoholic fatty liver disease (NAFLD), also named metabolic dysfunction-associated fatty liver disease (MAFLD), is a progressive disease spectrum encompassing simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. It is a clinically silent disease leading to multiple extra-hepatic complications/comorbidities. It is an independent risk factor for cardiovascular disease (CVD), increasing susceptibility to hypertension, atherosclerosis, arrhythmia, myocardial dysfunction, cardiac valve deformation, and venous thrombosis through putative mechanisms including systemic inflammation, endothelial dysfunction, oxidative stress, insulin resistance, and altered lipid metabolism. Eventually, it increases the CVD prevalence, incident, and fatality, contributing to a huge health care burden. In fact, CVD is becoming the leading cause of mortality among patients with NAFLD. Other cardiometabolic risk factors coexisting with NAFLD may also accelerate the synergistic development of CVD, which warrants assessment targeting hypertension, diabetes mellitus (DM), obesity, and dyslipidemia to be an integral part of NAFLD care. Monitoring metabolic biomarkers (glucose, glycosylated hemoglobin [HbA1c], insulin, lipids, and lipoproteins), cardiovascular (CV) risk scores (American College of Cardiology/American Heart Association [ACC/AHA] or Framingham), and subclinical atherosclerosis (coronary artery calcification [CAC], carotid intima-media thickness [CIMT], and carotid plaque) are recommended for risk prediction and reduction. There is no universally accepted treatment for NAFLD, and lifestyle changes with weight loss of at least 10% are the mainstay of management. Combination therapy of ezetimibe and statins have a cardioprotective effect and help reduce liver fat. Despite being an emerging risk factor for CVD and its rapidly increasing pattern affecting a quarter of the global population, NAFLD remains overlooked and undetected, unlike the other traditional risk factors. Hence, we conducted a comprehensive narrative review to shed more light on the importance of screening CVD in NAFLD patients. PubMed indexed relevant articles published from 2002 to 2022 (20 years) were searched in April 2022 using medical subject headings (MeSH) as "nonalcoholic fatty liver disease" [Mesh] AND "cardiovascular diseases" [Mesh]. Evidence from 40 observational studies, three clinical trials, one case series, 45 narrative reviews, four systematic reviews and meta-analyses, three systematic reviews, and one meta-analysis were summarized on the epidemiologic data, pathophysiologic mechanisms, clinical features, diagnostic modalities, overlapping management, perceived challenges and health literacy regarding the CVD risk attributed to NAFLD. Cureus 2022-05-30 /pmc/articles/PMC9242599/ /pubmed/35783879 http://dx.doi.org/10.7759/cureus.25495 Text en Copyright © 2022, Hassen et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Cardiology
Hassen, Gashaw
Singh, Abhishek
Belete, Gizeshwork
Jain, Nidhi
De la Hoz, Ivonne
Camacho-Leon, Genesis P
Dargie, Nitsuh K
Carrera, Keila G
Alemu, Tadesse
Jhaveri, Sharan
Solomon, Nebiyou
Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease
title Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease
title_full Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease
title_fullStr Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease
title_full_unstemmed Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease
title_short Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease
title_sort nonalcoholic fatty liver disease: an emerging modern-day risk factor for cardiovascular disease
topic Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242599/
https://www.ncbi.nlm.nih.gov/pubmed/35783879
http://dx.doi.org/10.7759/cureus.25495
work_keys_str_mv AT hassengashaw nonalcoholicfattyliverdiseaseanemergingmoderndayriskfactorforcardiovasculardisease
AT singhabhishek nonalcoholicfattyliverdiseaseanemergingmoderndayriskfactorforcardiovasculardisease
AT beletegizeshwork nonalcoholicfattyliverdiseaseanemergingmoderndayriskfactorforcardiovasculardisease
AT jainnidhi nonalcoholicfattyliverdiseaseanemergingmoderndayriskfactorforcardiovasculardisease
AT delahozivonne nonalcoholicfattyliverdiseaseanemergingmoderndayriskfactorforcardiovasculardisease
AT camacholeongenesisp nonalcoholicfattyliverdiseaseanemergingmoderndayriskfactorforcardiovasculardisease
AT dargienitsuhk nonalcoholicfattyliverdiseaseanemergingmoderndayriskfactorforcardiovasculardisease
AT carrerakeilag nonalcoholicfattyliverdiseaseanemergingmoderndayriskfactorforcardiovasculardisease
AT alemutadesse nonalcoholicfattyliverdiseaseanemergingmoderndayriskfactorforcardiovasculardisease
AT jhaverisharan nonalcoholicfattyliverdiseaseanemergingmoderndayriskfactorforcardiovasculardisease
AT solomonnebiyou nonalcoholicfattyliverdiseaseanemergingmoderndayriskfactorforcardiovasculardisease